HTLV-1 can be involved in acceleration of different nonhematological cancers
Journal Title: Journal of Cancer Research & Therapy - Year 2019, Vol 7, Issue 1
Abstract
In the past two decades it has been found that viral proteins might contribute to activation of numerous pathways involved in different types of cancer. Human T-lymphotropic virus 1 (HTLV-1), well known as a cause of T-cell leukemia, was found in patients having different types of cancers. Initiation and development of cancers is usually a multi-year multistep process that starts with initiation of the first somatic mutation and the then the next set of steps with the occurrence of an increasing number of somatic mutations with specific times for each one. Here we suggest a hypothesis: If HTLV-1 virus can infect the nonhematological cell, its viral proteins can work as the agents activating the general cancer-related pathways. This way Tax HTLV-1 protein (and/or other viral proteins) can serve in the similar way as the somatic mutation of specified genes and the presence of Tax can affect the functionality of several pathways that are not yet activated by the timeline of the stages of a “normal” cancer development. For example, the pathways PI3K, p53, TGF-β can be correspondingly be activated and inhibited by Tax before their functional change would appear by the timeline of a “normal” cancer development. The HTLV-1 infection-related KEGG pathway was found when the sets of the most frequently mutated genes for several cancers were analyzed by the DAVID program program (that selects the most probable pathways for a set of selected genes). These findings support the hypotheses that HTLV-1 infection can be a common factor in the development of very different cancers, thus warranting further exploration.
Authors and Affiliations
Valentina L Kouznetsova, Steven Chen, Igor F Tsigelny
Keywords
Related Articles
- EP ID EP534963
- DOI 10.14312/2052-4994.2019-1
- Views 78
- Downloads 0
Inhibition of glycolysis and growth of colon cancer cells by 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) in combination with butyrate, 2-deoxy glucose, 3-bromopyruvate or biguanides
Introduction: Glycolysis shows a positive correlation with growth of human colon cancer cells. PFKFB3 is an important enzyme regulating glycolysis in many tumor cells and presents a target for cancer chemotherapy. We stu...
Total meso-esophagogastrectomy in surgically resectable Siewert type II-III junctional gastric cancer: Safety and long term oncologic outcome
Aim: To analyze our experience confronting meso-esophagogastric resection (transhiatally extended total gastrectomy en-bloc with its inviolate primitive dorsal and ventral mesenterium) to less radical planes of surgery (...
Development of a new formulation of interferons (HEBERPAG) for BCC treatment
Purpose: This work is aimed to show briefly, the clinical development of a new pharmaceutical formulation of interferons for the treatment of basal cell carcinoma. Methods: A rationale design of the combination of IFN-α2...
Factors associated with first-line bevacizumab use in advanced non-squamous non-small cell lung cancer
Introduction: Bevacizumab was approved for treatment of advanced non-squamous, non-small cell lung cancer (NSCLC) in the US in late 2006. Information on its uptake and patient and tumor factors associated with its use is...
Usefulness of the Glasgow prognostic score for predicting survival in patients with resected non-small cell lung cancer
Background: Few studies have investigated whether the Glasgow prognostic score (GPS), an inflammation based prognostic score, is useful for postoperative prognosis of non-small cell lung cancer (NSCLC). Materials and met...